Champions Oncology , Inc. (NASDAQ: NASDAQ:CSBR), a research-driven company focused on developing advanced technology solutions and services to personalize the development and use of oncology drugs, reported its first-quarter fiscal year 2025 earnings results, demonstrating continued financial improvement and operational efficiency.
The company announced a revenue of $14.1 million for the quarter, marking a 12% increase from the first quarter of the previous year and reflecting a second consecutive quarter of revenue exceeding $14 million.
Key Takeaways
- Champions Oncology reports a revenue of $14.1 million, a 12% increase from the same period last year.
- Income from operations is $1.3 million, compared to a loss of $2.6 million in the previous year.
- Adjusted EBITDA for the quarter stands at $2 million, a significant improvement from an adjusted loss of $1.7 million year-over-year.
- Operational efficiencies led to reduced costs and improved gross margins, which are now at 50%.
- R&D expenses decreased by $1.3 million, with a focus on strategic investments.
- The company ended the quarter with $2.9 million in cash and no debt.
Company Outlook
- Champions Oncology remains cautiously optimistic about continued improvements in its financial and operational performance.
- The company is well-positioned for sustainable revenue growth and profitability due to recent turnaround efforts.
- Champions Oncology is actively engaged in discussions to out-license several programs from its drug development subsidiary, Corellia.
- Despite a tight funding environment, the company is confident in its cash position and the ability to raise capital to support growth.
Bearish Highlights
- The biotech sector has shown weakness, and tightness in capital markets has impacted R&D budgets.
- Operational issues within the company previously led to cost inefficiencies and delays in revenue recognition.
Bullish Highlights
- Champions Oncology has seen improvements in its operations, leading to increased profitability.
- The company's unique and first-in-class PDX bank and data platforms continue to drive business with pharma and biotech companies.
Misses
- There were no specific "misses" mentioned in the earnings call regarding financial targets or expectations.
Q&A Highlights
- CEO Ronnie Morris commented on the improving funding environment, noting that while it's not yet at the level of a few years ago, it is better than last year.
- The company has seen improvements in revenue conversion rates and a reduction in cancellation rates.
- The potential impact of the BIOSECURE Act was discussed, with Morris indicating that it could provide an opportunity for Champions Oncology to gain market share.
Champions Oncology's focus on operational efficiency and strategic investment in its core business has resulted in a positive start to the fiscal year. The company's management team expressed confidence in the continued momentum and the ability to deliver value for shareholders. As Champions Oncology looks ahead, it remains committed to its mission of advancing drug development and translational research for its pharmaceutical and biotech partners.
InvestingPro Insights
Champions Oncology, Inc. (NASDAQ: CSBR) has presented a promising start to its fiscal year 2025, showcasing a robust increase in revenue and operational improvements. To further understand the company's financial health and market position, here are some key insights from InvestingPro:
InvestingPro Data indicates that Champions Oncology has a market capitalization of $55.33 million, signaling a modest size within the biotech sector. The company's P/E ratio stands at -7.97, reflecting that it is not currently profitable. Despite a 12% increase in revenue for the quarter, the company's revenue growth over the last twelve months as of Q4 2024 has seen a decline of 6.9%. This could be indicative of the challenges faced in the biotech sector and the competitive nature of oncology drug development services.
An InvestingPro Tip highlights that Champions Oncology's short-term obligations exceed its liquid assets, which may require careful financial management in the near future, especially considering that analysts do not anticipate the company will be profitable this year. The company operates with a moderate level of debt, which is a balancing act given its current non-profitable status over the last twelve months.
For shareholders and potential investors looking for additional insights, InvestingPro offers a comprehensive list of tips, with 4 more tips available at https://www.investing.com/pro/CSBR, which can provide a deeper understanding of Champions Oncology's financial nuances and strategic positioning.
In summary, while Champions Oncology is showing positive signs in its operational performance, the InvestingPro Insights reveal that there are financial metrics that warrant careful consideration as the company navigates the competitive and capital-intensive biotech landscape.
Full transcript - Champions Oncology Inc (CSBR) Q1 2025:
Operator: Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2025 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded. I will now turn the conference over to your host, Ronnie Morris, Chief Executive Officer. You may begin.
Ronnie Morris: Good afternoon. I am Ronnie Morris, CEO of Champions Oncology. Joining me today is David Miller, our Chief Financial Officer. Thank you for joining us for our quarterly earnings call. Before I begin, I will remind you that we'll be making forward-looking statements during today's call and that actual results could differ materially from what are described in those statements. Additional information on factors that could cause results to differ is available on our Forms 10-Q and Form 10-K. A reconciliation of non-GAAP financial measures that may be discussed during the call to GAAP financial measures is available in the earnings release. I will start by pointing out that our prepared comments for today will be relatively brief, as we just recently provided our fiscal year-end results and company update six weeks ago. On our year-end call, I provided an update on the difficulties we encountered last year, which led to disappointing financial results compared to our historical performance. I indicated that these challenges stem from a combination of external and internal factors. Externally, the weakness and retraction in the biotech sector, including tightness in the capital markets negatively affected our customers' R&D budgets, resulting in fewer biotech signing studies as well as a decrease in our average study size. This led to a decrease in our bookings growth and revenue. Internally, we were hampered by operational issues that led to cost inefficiencies and delays in revenue recognition, putting pressure on our bottom line. On a more positive note, I highlighted that we ended the year strongly with significant trend reversals beginning to emerge. Improvements in our operations began to take hold and some of the external pressures appear to be easing. The reversal was supported by our Q4 revenue in excess of $14 million and an adjusted quarterly profit. Most importantly, I indicated that we were cautiously optimistic that the turnaround was not limited to the quarter, and that the changes we are making were leading to a stronger and leaner company well positioned for a return to sustainable revenue and profitability. As we begin this fiscal year, I'm encouraged to report that the positive momentum which began last quarter has continued. We have begun the year with another good revenue quarter, in excess of $14 million, improved operational efficiency and scalability, all leading to expanded profitability. The next several quarters will not be without its challenges and some volatility in our financial results, but we are confident that we have rightsized the company to accentuate the positive and minimize any negative impact when obstacles are encountered. Our business continues to be driven by a unique and first-in-class PDX bank, our precise and reproducible well-characterized data and our expanded In vivo and Ex vivo platforms, which combine to provide pharma and biotech companies, the necessary insights to further their drug development and translational needs. With regard to Corellia, our wholly-owned drug development subsidiary, there is not much to add from our year-end call. I will reiterate that we continue to be excited about the targets and compounds that we have developed. We are actively engaged in discussions to out-license several of our programs. As with all our cost centers, we are cognizant of the impact on our bottom line results. As such, we are working to minimize our cost by reducing our spend while being careful not to harm the targets development, simultaneously searching for a potential licensee. The funding environment remains tight, but we continue to be actively engaged with investors in an effort to raise capital to support and accelerate our growth. In summary, the quarter's performance represented a second sequential quarter of overall improvements in our results and operations. We anticipate that we will continue to solidify these achievements over the coming quarters and put us back on track to provide consistently positive results for our investors. Our comprehensive platform, our unique data, our stellar reputation and strong team are the key ingredients for our positive outlook. We are confident that we will continue to become stronger with revenue and profitability over the longer term. Now let me turn the call over to David Miller for a more detailed review of the financial results.
David Miller: Thanks, Ronnie. Our full results on Form 10-Q will be filed with the SEC by Monday, September 16. Our first quarter revenue was $14.1 million, an increase of 12% from the first quarter of 2024. As highlighted on our year-end call and reiterated by Ronnie, the financial turnaround began last quarter and continued with our second consecutive quarter of revenue in excess of $14 million. On a GAAP basis, our income from operations for the first quarter of 2025 was $1.3 million, compared to a loss of $2.6 million in the prior year. Included in the income of $1.3 million were non-cash expenses of stock comp and depreciation, totaling approximately $700,000. Excluding these non-cash items, our adjusted EBITDA was $2 million for the quarter, compared to an adjusted loss of $1.7 million in the year-ago period. Turning the focus to our cash-based results, total cost of sales was $7 million, compared to $7.5 million in our first quarter last year, a decline of 6%. The decline was primarily due to operational efficiencies implemented, which had a dual effect of reducing the amount of repeat work and the associated costs while increasing our revenue conversion. Due to the decrease in cost of sales while increasing revenue by $1.5 million, our gross margin for the quarter improved to 50%, compared to 40% for the same period last year. Our margins will fluctuate over the next few quarters with some expected volatility in revenue and cost of sales, but over the long-term, with the stabilization in our costs, we anticipate delivering margins in excess of 50% as our revenue grows. For the quarter, R&D expense was approximately $1.5 million, compared to $2.8 million in the year-ago period, a decline of $1.3 million. We have a renewed emphasis on our bottom line results, and we've strategically reduced our R&D expense. We continue to invest in our core business to facilitate future growth, but we've been more judicious in our investment in developmental programs that are not part of our core vision. Approximately $600,000 was invested towards our drug discovery efforts during the quarter compared to $1.2 million last year. For the quarter, sales and marketing expense was a flat $1.6 million. Our G&A expense was $1.9 million compared to $2.3 million in the year-ago period, a decrease of $400,000. The decrease was primarily due to a reduction in compensation and recruitment expenses. Now turning to cash. We ended the quarter with $2.9 million of cash on the balance sheet and no debt. For the quarter, cash generated by operating activities was $300,000. The cash generation was led by an improvement in our operating results, along with changes in our working capital accounts in the ordinary course of business. As our operational results continue to stabilize and improve, we anticipate a gradual increase in our cash balance. Accordingly, we are confident that our cash position remains solid. In summation, our first quarter financial results were strong, with revenue in excess of $14 million and adjusted EBITDA of $2 million. There will be some volatility in revenue and EBITDA over the year, but with the expected strength in our bookings and with the operational corrections taking effect, we're confident that we've returned to the path of delivering stronger financial results that should create value for our shareholders. We look forward to our next update in mid-December when we report our second quarter results. We will now open the call to questions.
Operator: Thank you. At this time, we will be conducting a question-and-answer session. [Operator Instructions] The first question comes from Matt Hewitt with Craig-Hallum. Please proceed.
Matthew Hewitt: Good afternoon and thank you for taking the questions and congratulations on the strong quarter. Maybe first up, I'd love it if you could provide a little bit of color on what you're hearing from customers. I think you noted that the funding environment has gotten a little bit better. But what are you hearing from customers? And even if you could delineate that between the smaller, midsize customers versus larger customers, there's been some – I don't want to say concern, but some comments here recently regarding the larger customers' reprioritization of pipelines, those types of things. I'm just curious what you're hearing?
Ronnie Morris: Hey. Matt, thanks. Yes, so I don't know that we have a scientific answer for that, but I'll give you kind of our gestalt and some anecdotes. We feel that it's still not the way it was, let's say, a couple of years ago, but it's better than it was a year-ago. So it's improving. To the degree it's improving, it's hard to really tell you. I would say that from our experiences, it's still tight in the small biotech world, whereas in the midsized to the larger pharma they are definitely cutting back, but they have budget, and they are continuing to do work. So for our services, the preclinical services, using our unique and first-in-class PDX bank, I think that's a place where they need to continue to spend. So from our perspective, it's definitely getting better, but it's not where it was, let's say, a couple of years ago, and we think it will get there. It might just take another year or so.
Matthew Hewitt: Okay. That's much appreciated. Last quarter, you noted that the conversion rates were improving. Cancellation rates were down. Did that trend continue here into the first quarter?
Ronnie Morris: Yes. Yes. We've seen that both of those things are happening. Our revenue is converting better and as a result of our cancellations being down as well. So those are two really positive aspects to the first quarter as well as the fourth quarter that we had talked about. So things are definitely moving in the right trend – right direction.
Matthew Hewitt: That's great. And maybe one last one, and I'll hop back in the queue. But on Monday afternoon, the BIOSECURE Act was passed in the House, now it moves on to the Senate. I'm just curious, do you guys compete against one or more of the entities listed in that bill? And if so, would their being blocked in the – here in the U.S. market, would that create an opportunity for you to pick up some share? Thank you.
Ronnie Morris: Yes. So I think for a long time, certain companies have stayed away from working with some of those groups. I think it probably will help us. I don't know to what extent, but I think it probably will help us because certainly, some of those companies, to a certain extent, we compete with. So...
Matthew Hewitt: Got it. Well, that's great news. Thank you.
Ronnie Morris: Thanks, Matt.
Operator: [Operator Instructions] Okay. We currently have no questions in queue. I'd like to turn it back to management. [Operator Instructions]
Ronnie Morris: Hello.
Operator: Just polling for questions.
Ronnie Morris: Sure. No problem.
Operator: Okay. I'd like to turn the floor back to management for any closing remarks.
Ronnie Morris: Great. Well, thank you, everybody, for joining us for our quarterly earnings call. We certainly are excited to continue the positive trend, getting back to profitability and the growth. We are excited about how we deliver our results, the quality, our teams, the work we do – the important work we do with our pharmaceutical and the biotech partners and customers. And we look forward to updating everybody in a couple of months to our continued progress. So everyone, have a good evening, and thank you for joining us.
Operator: Thank you. This concludes today's conference, and you may disconnect your lines at this time. Thank you for your participation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.